Method Transfer from an Agilent 1100 Series LC System to an ACQUIT Y UPLC H-Class System with Gradient SmartStart Tec hnology: Analysis of an Active P harmaceutical Ingredient and Related Substances

Significance of the Topic

The reliable transfer of chromatographic methods between HPLC and UHPLC platforms is critical in pharmaceutical analysis to ensure consistent assay performance, maintain system suitability criteria, and support regulatory compliance. Efficient method transfer minimizes development time, reduces costs, and preserves analytical robustness when adopting high-throughput UPLC technology.

Objectives and Study Overview

This study describes the transfer of a gradient-based assay for abacavir and its related substances from an Agilent 1100 Series LC System to an ACQUITY UPLC H-Class System using Gradient SmartStart Technology. Key goals included maintaining separation quality and retention time consistency without altering the original gradient program.

Methodology

Sample preparation involved dissolving abacavir and known impurities in water. Chromatographic conditions on the source system were: a CORTECS C18 column (2.7 µm, 4.6 × 75 mm), mobile phase A (0.1% trifluoroacetic acid in water), mobile phase B (85% methanol in water), flow rate 1.85 mL/min, column temperature 36 °C, detection at 245 nm, and a linear gradient from 5% to 30% B over 6.38 min and to 90% B by 10.37 min. Gradient SmartStart Technology on the target system automatically adjusted the dwell volume offset to mirror retention profiles.

Used Instrumentation

• Agilent 1100 Series LC System with PDA detector
• ACQUITY UPLC H-Class System with UPLC PDA Detector and CH-A module

Main Results and Discussion

Retention times for the five analytes were nearly identical between systems (e.g., abacavir at 6.34 min versus 6.40 min). System suitability metrics, including resolution and peak symmetry, met original method criteria without modifying the gradient table. The dwell volume compensation via SmartStart preserved the elution order and separation selectivity, demonstrating robust method equivalence.

Benefits and Practical Applications

• Seamless migration of legacy HPLC assays to UPLC platforms
• Elimination of manual gradient recalculations
• Time savings in method validation and regulatory submission
• Enhanced laboratory throughput and resource efficiency

Future Trends and Possibilities

Advancements may include integrated software for automated method transfer across varied vendor platforms, AI-driven optimization of dwell volume corrections, and digital tools to predict system suitability outcomes. Broader adoption of SmartStart-like technologies will further streamline cross-platform scalability in pharmaceutical QC and R&D.

Conclusion

The abacavir and related substances assay was successfully transferred from an Agilent 1100 Series LC System to an ACQUITY UPLC H-Class System. Gradient SmartStart Technology ensured equivalent separation and system suitability without altering the original gradient program, highlighting an efficient approach for method modernization.

References

Technical Brief 720005252EN, Waters Corporation.